Elanco Animal Health Incorporated $ELAN Shares Acquired by Amalgamated Bank

Amalgamated Bank lifted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 793.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 226,580 shares of the company’s stock after purchasing an additional 201,226 shares during the quarter. Amalgamated Bank’s holdings in Elanco Animal Health were worth $4,563,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC raised its position in Elanco Animal Health by 322.0% during the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after buying an additional 2,468,122 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the period. Primecap Management Co. CA increased its stake in shares of Elanco Animal Health by 3.1% during the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after acquiring an additional 1,543,279 shares during the period. Norges Bank purchased a new position in Elanco Animal Health during the second quarter worth about $12,502,000. Finally, Brandes Investment Partners LP lifted its position in Elanco Animal Health by 11.3% in the second quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after purchasing an additional 820,901 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Up 0.9%

NYSE:ELAN opened at $24.38 on Thursday. The company has a market capitalization of $12.11 billion, a PE ratio of 406.32, a price-to-earnings-growth ratio of 3.36 and a beta of 1.87. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $24.98. The stock has a fifty day simple moving average of $22.62 and a 200-day simple moving average of $19.87.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the company earned $0.13 EPS. The firm’s revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, CFO Robert M. Vanhimbergen acquired 6,950 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $21.64 per share, with a total value of $150,398.00. Following the purchase, the chief financial officer directly owned 124,233 shares in the company, valued at approximately $2,688,402.12. This trade represents a 5.93% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider Rajeev A. Modi acquired 4,500 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $21.33 per share, with a total value of $95,985.00. Following the completion of the transaction, the insider directly owned 123,082 shares in the company, valued at approximately $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 43,450 shares of company stock valued at $937,883 over the last three months. Company insiders own 0.89% of the company’s stock.

Wall Street Analyst Weigh In

ELAN has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $24.00 in a report on Tuesday, October 7th. Zacks Research cut Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Finally, Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.78.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.